SRR1797239
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.460
- ANDROGEN_RESPONSE+0.440
- MTORC1_SIGNALING+0.410
- OXIDATIVE_PHOSPHORYLATION+0.330
- CHOLESTEROL_HOMEOSTASIS+0.320
- APOPTOSIS+0.310
- HYPOXIA+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- MYC_TARGETS_V1+0.260
- P53_PATHWAY+0.240
Top 10 suppressed
- KRAS_SIGNALING_DN-0.270
- WNT_BETA_CATENIN_SIGNALING-0.100
- ALLOGRAFT_REJECTION-0.080
- ANGIOGENESIS-0.080
- APICAL_SURFACE-0.060
- BILE_ACID_METABOLISM-0.060
- COAGULATION-0.060
- MYOGENESIS-0.060
- APICAL_JUNCTION-0.050
- KRAS_SIGNALING_UP-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013491 | — | cohortA1 | 0.824 |
| 2 | BS_1A6MQ9ZA | high-grade glioma | — | 0.824 |
| 3 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.818 |
| 4 | R315 | — | — | 0.813 |
| 5 | SRR6079985 | — | — | 0.809 |
| 6 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.804 |
| 7 | SRR2932814 | — | — | 0.797 |
| 8 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.796 |
| 9 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.790 |
| 10 | 23B8A53B-83FD-47BB-AD6E-184E11B1E957 | — | — | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |